Home » Archive by Category

Xconomy

Biotech Unveils Drug for Viral Infections Tied to Cervical Cancer

August 22, 2014 – 4:00 am | Edit Post
Biotech Unveils Drug for Viral Infections Tied to Cervical Cancer

A small San Diego biotech has identified a drug that appears to prevent several subtypes of the human papillomavirus (HPV) from replicating—including the two HPV subtypes that cause 70 percent…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Ebola, Mapp, Tekmira, ViaCyte & More

August 21, 2014 – 11:09 am | Edit Post
West Coast Biotech Roundup: Ebola, Mapp, Tekmira, ViaCyte & More

Big news this morning: two Americans treated with an experimental Ebola treatment have recovered and are now out of the hospital. (A third person, a Spaniard, who received the treatment unfortunately…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Ebola, Mapp, Tekmira, ViaCyte & More

August 21, 2014 – 11:09 am | Edit Post
West Coast Biotech Roundup: Ebola, Mapp, Tekmira, ViaCyte & More

Big news this morning: two Americans treated with an experimental Ebola treatment have recovered and are now out of the hospital. (A third person, a Spaniard, who received the treatment unfortunately…

[[Click headline to continue reading.]]

Sanford-Burnham Seeks Improved Pharma Ties with New CEO from GSK

August 19, 2014 – 5:02 pm | Edit Post
Sanford-Burnham Seeks Improved Pharma Ties with New CEO from GSK

Following an executive search that took about 18 months, San Diego’s Sanford-Burnham Medical Research Institute named a new CEO today. He is Perry Nisen, a pediatric cancer specialist who specialized…

[[Click headline to continue reading.]]

Sanford-Burnham Seeks Improved Pharma Ties with New CEO from GSK

August 19, 2014 – 5:02 pm | Edit Post
Sanford-Burnham Seeks Improved Pharma Ties with New CEO from GSK

Following an executive search that took about 18 months, San Diego’s Sanford-Burnham Medical Research Institute named a new CEO today. He is Perry Nisen, a pediatric cancer specialist who specialized…

[[Click headline to continue reading.]]

HealthQuest Capital Raises $110M for Debut Fund with Medtech Focus

August 19, 2014 – 3:00 am | Edit Post
HealthQuest Capital Raises $110M for Debut Fund with Medtech Focus

HealthQuest Capital, founded last year by Sofinnova Ventures partner Garheng Kong, says it has raised $110 million for its debut fund and already has invested in several medical technology and…

[[Click headline to continue reading.]]

HealthQuest Capital Raises $110M for Debut Fund with Medtech Focus

August 19, 2014 – 3:00 am | Edit Post
HealthQuest Capital Raises $110M for Debut Fund with Medtech Focus

HealthQuest Capital, founded last year by Sofinnova Ventures partner Garheng Kong, says it has raised $110 million for its debut fund and already has invested in several medical technology and…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Onyx, Calico, Otonomy, Dendreon & More

August 14, 2014 – 11:35 am | Edit Post
West Coast Biotech Roundup: Onyx, Calico, Otonomy, Dendreon & More

[Corrected 8/14/14, 8:11pm. See below.] When Amgen (NASDAQ: AMGN) bought South San Francisco-based Onyx Pharmaceuticals last year for $10.4 billion, it expected great things from Onyx’s…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Onyx, Calico, Otonomy, Dendreon & More

August 14, 2014 – 11:35 am | Edit Post
West Coast Biotech Roundup: Onyx, Calico, Otonomy, Dendreon & More

[Corrected 8/14/14, 8:11pm. See below.] When Amgen (NASDAQ: AMGN) bought South San Francisco-based Onyx Pharmaceuticals last year for $10.4 billion, it expected great things from Onyx’s…

[[Click headline to continue reading.]]

Otonomy Hears Wall Street Ovation as Some Life Sciences IPOs Dim

August 13, 2014 – 4:23 pm | Edit Post
Otonomy Hears Wall Street Ovation as Some Life Sciences IPOs Dim

Auris Medical, the Swiss biotech focused on diseases and disorders of the ear, got the catchy ticker symbol (NASDAQ: EARS) when it went public last week. But San Diego’s Otonomy (NASDAQ: OTIC)…

[[Click headline to continue reading.]]